Immunprophylaxe der Hepatitis B - DGVS

Literatur
1 Empfehlungen der Ständigen Impfkommission (STIKO) am Robert-
Koch-Institut/Stand Juli 2002. Epidem Bull 2002; 28: 227 – 242 (IV)
2 Virushepatitis B und C bis zum Jahr 2001. Epidem Bull 2002; 44:
369–373 (IV)
3 Seaworth B, Drucker J, Starling J et al. Hepatitis B vaccines in patients
with chronic renal failure before dialysis. J Infect Dis 1988; 157:
332– 337 (III)
4 Thierfelder W, Meisel H, Schreier E et al. Die Prävalenz von Antikörpern
gegen Hepatitis-A-, Hepatitis-B- und Hepatitis-C-Viren in der
deutschen Bevölkerung. Gesundheitswesen 1999; 61 (Sonderheft 2):
S110–S114 (Ib)
5 Jilg W, Hottenträger B, Weinberger K et al. Prevalence of markers for
hepatitis B in the adult German population. J Med Virol 2001; 63:
96–102 (Ib)
6 Coates T, Wilson R, Patrick G et al. Hepatitis B vaccines: Assessment of
the seroprotective efficacy of two recombinant DNA vaccines. Clin
Ther 2001; 23: 392–403 (Ia)
7 Hadler SC, Francis DP, Maynard JE et al. Long-term immunogenicity
and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med
1986; 315: 209 – 214 (Ib)
8 Jilg W, Schmidt M, Deinhardt F. Four-year experience with a recombinant
hepatitis B vaccine. Infection 1989; 17: 70–76 (IIa)
9 West DJ, Calandra G. Vaccine induced immunologic memory for hepatitis
B surface antigen: implications for policy on booster vaccination.
Vaccine 1996; 14: 1019–1027 (III)
10 Wainwright RB, Bulkow LR, Parkinson AJ et al. Protection provided by
hepatitis B vaccine in a Yupik escimo population – results of a 10-year
study. J Infect Dis 1997; 175: 674 – 677 (IIa)
11 Anonymous. Are booster immunisations needed for lifelong hepatitis
B immunity? European Consensus Group on Hepatitis B Immunity.
Lancet 2000; 355: 561–565 (IV)
12 Banatvala J, Van Damme P, Oehen S. Lifelong protection against hepatitis
B: the role of vaccine immunogenicity in immune memory. Vaccine
2000; 19: 877–885 (III)
13 Wismans PJ, van Hattum J, Mudde GC et al. Is booster injection with
hepatitis B vaccine necessary in healthy responders? A study of the
immune response. J Hepatol 1989; 8: 236 –240 (IIa)
14 Resti M, Azzari C, Manelli F et al. Ten-year follow-up study of neonatal
hepatitis B immunization: are booster injections indicated? Vaccine
1997; 12/13: 1338– 1340 (IIb)
15 Da Villa G, Pellicia MG, Peluso F et al. Anti-HBs responses in children
vacinated with different schedules of either plasma-derived or HBV
DNA recombinant vaccine. Res Virol 1997; 148: 109 –114 (IIb)
16 Watson B, West DJ, Chilkatowsky A et al. Persistence of immunologic
memory for 13 years in recipients of a recombinant hepatitis B vaccine.
Vaccine 2001; 19: 3164 – 3168 (IIb)
17 Liao SS, Li RC, Li H et al. Long-term efficacy of plasma-derived hepatitis
B vaccine: a 15-year follow-up study among Chinese children. Vaccine
1999; 17: 2661 –2666 (IIb)
18 Whittle H, Jaffar S, Wansbrough M et al. Observational study of vaccine
efficacy 14 years after trial of hepatitis B vaccination in Gambian
children. BMJ 2002; 325: 569 – 574 (IIa)
19 Wismans P, van Hattum J, Stelling T et al. Effect of supplementary vaccination
in healthy non-responders to hepatitis B vaccination. Hepatogastroenterol
1988; 35: 78 –79 (IIb)
20 Jilg W, Schmidt M, Deinhardt F. Impfversager nach Hepatitis B-Impfung:
Effekt zusätzlicher Impfungen. Dtsch Med Wschr 1990; 115:
1545 – 1548 (IIb)
21 Clemens R, Sänger R, Kruppenbacher J et al. Booster immunization of
low- and non-responders after a standard three dose hepatitis B vaccine
schedule – results of a postmarketing surveillance. Vaccine 1997;
15: 349–352 (IIb)
22 Hasselhorn HM, Kralj N, Hofmann F et al. [Non- and low-response after
preventive hepatitis B vaccination]. Gesundheitswesen 1997; 59:
321 – 328 (III)
23 Rendi-Wagner P, Wiedermann G, Stemberger H et al. New vaccination
strategies for low- and non-responders to hepatitis B vaccine. Wien
Klin Wochenschr 2002; 114: 175 –180 (III)
24 Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in
health care workers. Response rate and experiences from vaccination
in clinical practise. Scand J Infect Dis 1999; 31: 197 – 200 (IIb)
25 Carlsson T, Struve J, Sonnerborg A et al. The anti-HBs response after 2
different accelerated intradermal and intramuscular schemes for hepatitis
B vaccination. Scand J Infect Dis 1999; 31: 93 – 95 (IIa)
26 Henderson EA, Louie TJ, Ramotar K et al. Comparison of higher-dose
intradermal hepatitis B vaccination to standard intramuscular vaccination
of healthcare workers. Infect Control Hosp Epidemiol 2000;
21: 264 – 2649 (Ib)
27 Rahman F, Dahmen A, Herzog-Hauff S et al. Cellular and humoral immune
responses induced by intradermal or intramuscular vaccination
with the major hepatitis B surface antigen. Hepatology 2000; 31:
521 – 527 (IIb)
28 Anonymous. Immunisation against hepatitis B. Lancet 1988; i:
875 –876 (IV)
29 Bruguera M, Rodicio JL, Alcazar JM et al. Effects of different dose levels
and vaccination schedules on immune response to a recombinant
DNA hepatitis B vaccine in haemodialysis patients. Vaccine 1990;
Suppl: S47–S49 (IIa)
30 Marangi AL, Giordano R, Montanaro A et al. Hepatitis B virus infection
in chronic uremia: long-term follow-up of a two-step integrated protocol
of vaccination. Am J Kidney Dis 1994; 23: 537 – 542 (IIb)
31 Mitwalli A. Responsiveness to hepatitis B vaccine in immunocompromised
patients by doubling the dose scheduling. Nephron 1996; 73:
417 – 420 (IIb)
32 Rosman AS, Basu P, Galvin K et al. Efficacy of a high and accelerated
dose of hepatitis B vaccine in alcoholic patients: a randomized clinical
trial. Am J Med 1997; 103: 217 – 222 (Ib)
33 Mettang T, Schenk U, Thomas S et al. Low-dose intradermal versus intramuscular
hepatitis B vaccination in patients with end-stage renal
failure. A preliminary study. Nephron 1996; 72: 192 – 196 (III)
34 Propst T, Propst A, Lhotta K et al. Reinforced intradermal hepatitis B
vaccination in hemodialysis patients is superior in antibody response
to intramuscular or subcutaneous vaccination. Am J Kidney Dis 1998;
32: 1041 – 1045 (III)
35 Charest AF, McDougall J, Goldstein MB. A randomized comparison of
intradermal and intramuscular vaccination against hepatitis B virus
in incident chronic hemodialysis patients. Am J Kidney Dis 2000; 36:
976 – 982 (Ib)
36 Kapoor D, Aggarwal SR, Singh NP et al. Granulocyte-macrophage colony-stimulating
factor enhances the efficacy of hepatitis B virus vaccine
in previously unvaccinated haemodialysis patients. J Viral Hepat
1999; 6: 405 – 409 (Ib)
37 Anandh U, Bastani B, Ballal S. Granulocyte-macrophage colony-stimulating
factor as an adjuvant to hepatitis B vaccination in maintenance
hemodialysis patients. Am J Nephrol 2000; 20: 53 – 56 (Ib)
38 Evans TG, Schiff M, Graves B et al. The safety and efficacy of GM-CSF as
an adjuvant in hepatitis B vaccination of chronic hemodialysis patients
who have failed primary vaccination. Clin Nephrol 2000; 54:
138 – 142 (Ib)
39 Looney RJ, Hasan MS, Coffin D et al. Hepatitis B immunization of healthy
elderly adults: relationship between naive CD4 + T cells and primary
immune response and evaluation of GM-CSF as an adjuvant. J
Clin Immunol 2001; 21: 30 –36 (Ib)
40 AndrØ F, Zuckerman AJ. Review: Protective efficacy of hepatitis B vaccines
in neonates. J Med Virol 1994; 44: 144 – 151 (III)
41 Mitsui T, Iwano K, Suzuki S et al. Combined hepatitis B immune globulin
and vaccine for postexposure prophylaxis of accidental hepatitis B
virus infection in hemodialysis staff members: comparison with immune
globulin without vaccine in historical controls. Hepatology
1989; 10: 324– 327 (III)
Jilg W et al. Immunprophylaxe der Hepatitis … Z Gastroenterol 2004; 42: 698 –702
Gastro 0804 · Artikel 221f, 11.8.04 · reemers publishing services gmbh
Leitlinie 701